The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 6.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (14 analysts) rates it buy, with a mean price target of $92.
Sprouts Farmers Market, Inc.
SFM · Nasdaq · USD · Market cap $4.8B · 36,000 employees
Sprouts Farmers Market, Inc., together with its subsidiaries, engages in the retailing of fresh, natural, and organic food products in the United States.
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 04:19 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price52.07 USD at the 13 Nov 2026 close
- Our value readFair vs our fair value, as of 13 Nov 2026
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans slightly to calls (put/call 1.00)
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $40.50 to $61.95, base estimate $53.78 (screen dated 2026-11-13).
- Trend Distribution
- Insiders insiders sold, $1,142,774, latest filing 2026-11-04
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 1.00, read 2026-11-13
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Sprouts Farmers Market, Inc. holds its Distribution at $52.07. The statistical read favours the buyers, held for 6 days.
| Phase | Distribution · caution |
| Quantitative state | The statistical read favours the buyers, held for 6 days |
| Price at the screen | $52.07 |
| Valuation | 9.96 trailing · 11.86 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 0.79 |
Five Screens, Shown in Full
Does not pass. Debt ratio
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 46.73% | Below 33% | Interest-bearing debt is 46.7% of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 7.75% | Below 49% | Money owed to the company is 7.8% of assets, under the 49% limit. | Pass |
| Revenue purity | 0.06% | Below 5% | Only 0.1% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Sprouts Farmers Market,'s business is in a permissible area, but its interest-bearing debt is about 47% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when SFM's ethical verdict changes
Today SFM does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 13 Nov 2026: it trades at roughly a 3% discount to our $53.78 fair value, 4.70% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 3.2% discount to the base estimate.
Third-party analyst targets: 13 covering, consensus Hold. The average target sits +11% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $53.78, with a range of $40.50 to $61.95, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsOrganic Grocer Shows Profits But Little Spark
Walk into any Sprouts store and the shelves scream fresh, natural and organic. Yet behind the healthy glow sits a business adding revenue at just 4 percent a year while posting a 6 percent profit margin. The 37 percent return on equity looks impressive on paper, but the modest top-line growth leaves little room for meaningful expansion in a crowded grocery aisle.
We pass because the numbers do not clear our bar for a compelling opportunity. A forward multiple of 12.8 times earnings already prices in steady but unspectacular performance, and the unknown competitive moat adds further uncertainty. Analysts may cluster around a buy rating with a 92 dollar median target, yet our screen sees no edge worth pursuing.
Risk sits with execution in a defensive sector where pricing pressure and shifting consumer tastes can quickly erode margins. Currency and cyclical swings are limited here, but low growth still caps upside. Analysis, not advice.
| Forward P/E | 11.9xexpensive even after accounting for its growth |
| Trailing P/E | 10.0xvery cheap relative to earnings |
| EPS, trailing | 5.23 |
| EPS, forward | 4.39 |
| Revenue growth | +4.7%slow but positive growth |
| Profit margin | 5.4%thin but positive margins |
| Return on equity | 33.5%an exceptional return on shareholder capital |
| FCF yield | 7.66% |
| Debt to equity | 1.46a meaningful debt load worth watching |
| Current ratio | 0.97below 1: short-term bills exceed liquid assets |
| Beta | 0.79steadier than the market |
| Short interest, float | 0.15% |
| 52-week range | 47.35 - 94.89 |
| Market cap | $4.8B |
| Employees | 36,000 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeSFM trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 18.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (14 analysts) rates it buy, with a mean price target of $92.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (14 analysts) rates it buy, with a mean price target of $92. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (14 analysts) rates it buy, with a mean price target of $92. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (14 analysts) rates it buy, with a mean price target of $92. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (14 analysts) rates it buy, with a mean price target of $92. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (14 analysts) rates it buy, with a mean price target of $92. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (14 analysts) rates it buy, with a mean price target of $92. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (14 analysts) rates it buy, with a mean price target of $92. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (14 analysts) rates it buy, with a mean price target of $92. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- U.S. Targeted Value Portfolio (DFAT) Buys $3.7 Million More Coeur Mining on Wednesday Yahoo Finance · 3d ago
- What Is e.l.f. Beauty (ELF) Gaining From This 500 Store Clean Beauty Launch? Yahoo Finance · 3d ago
- Michael Burry buys back into Lululemon, adds to other positions Yahoo Finance · 4d ago
- Grocery Outlet's Q3 Earnings Preview: Is GO Stock Ready to Surprise? Yahoo Finance · 7d ago
- Well People Brings High-Performance Clean Beauty to Sprouts Farmers Market Yahoo Finance · 7d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-04 | Sinclair Jack | CEO | S - Sale+OE | 21,576 | $1,142,774 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-07-16 | Gil Cisneros | Democrat | buy | 15K–50K |
| 2026-07-16 | Gil Cisneros | Democrat | buy | 15K–50K |
| 2026-07-16 | Gil Cisneros | Democrat | buy | 15K–50K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $81.58 | +6.4% | · | $1,064 | +6.4% |
| 2 months | $77.17 | +12.5% | · | $1,125 | +12.5% |
| 3 months | $78.84 | +10.1% | · | $1,101 | +10.1% |
| 6 months | $79.92 | +8.6% | · | $1,086 | +8.6% |
| 1 year | $161.88 | -46.4% | · | $536 | -46.4% |
| 2 years | $76.13 | +14.0% | · | $1,140 | +14.0% |
| 3 years | $33.91 | +156.0% | · | $2,560 | +156.0% |
| 5 years | $29.00 | +199.4% | · | $2,994 | +199.4% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever SFM does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.